Detail of "47747-56-8"

Reference

Studies on clinical pharmacology

Studies on clinical pharmacology. XIII. Influence of antibiotics on antiedematigenous and antihistaminic activities of antiinflammatory drugs in simultaneous administration. Fujii, A.; Yoshizawa, M.; Mizuno, S.; Tamura, T. (Sch. Dent., Nihon Univ., Matsudo, Japan). Recent Adv.In this article, certain chemicals are used. Some of their cas registry numbers are 15686-71-2 and 22204-53-1 Chemother., Proc. Int. Congr. Chemother., 14th, Issue Antimicrobial Sect. 1, 679-80. Edited by: Ishigami, Joji. Univ. Tokyo Press: Tokyo, Japan. (English) 1985. CODEN: 55GNAX. DOCUMENT TYPE: Conference CA Section: 1 (Pharmacology) Simultaneous administration of antibiotics (ampicillin [69-53-4], talampicillin [47747-56-8], bacampicillin [50972-17-3], cephalexin [15686-71-2], and josamycin [16846-24-5]) and nonsteroidal antiinflammatory drugs (aspirin [50-78-2], fenoprofen Ca [34597-40-5], naproxen [22204-53-1], and indomethacin [53-86-1]) increased or slightly decreased antiedematigenous and antihistaminic activities of some antibiotics and antiinflammatory drugs in vivo and in vitro. Talampicillin and bacampicillin, prodrugs of ampicillin, possessed synergistic actions on both activities with antiinflammatory drugs. .

Pharmacological studies with carfecillin and talampicillin, two esters of broad-spectrum penicillins

Pharmacological studies with carfecillin and talampicillin, two esters of broad-spectrum penicillins. Reeves, D. S.; Bywater, M. J.; Holt, H. A.; Wilkinson, P. J. (Dep. Med. Microbiol., Southmead Hosp., Bristol, Engl.). Clin. Pharm. Clin. Pharmacol., Proc. Int. Symp., Meeting Date 1975, 223-34. Edited by: Gouveia, William A.; Tognoni, Gianni; Van der Kleijn, Eppo. Elsevier: Amsterdam, Neth. (English) 1976. CODEN: 35VMAF. DOCUMENT TYPE: Conference CA Section: 1 (Pharmacodynamics) Carfecillin (I) [27025-49-6] when given orally at 500 and 1000 mg dosages to human subjects failed to produce adequate blood level of carbenicillin (II) [4697-36-3] required to protect against Psedumonas aeruginosa infection. Repeated doses of 100 mg every 8 h for 4 days showed no evidence of accumulation. In patients with renal insufficiency 1000 mg I given orally at 4-h intervals gave the highest mean level of 30 mg II/L; not sufficient for reliable antipseudomonal therapy. Urinary excretion after a 1000 mg dose of I provided appropriate urinary level (mean 434 mg/L) for antipseudomonal therapy of urinary infection. Oral administration of 500 mg talampicillin (II) [47747-56-8]to healthy human subjects provided a higher mean peak serum level of ampicillin [69-53-4] and occurred sooner than after a larger equiv. dose of ampicillin. Similar results were obtained for urinary concn. in healthy subjects and both serum and urinary concn., with some variability, in patients undergoing treatment with ampicillin or III. The potential hepatotoxicity of III which is the phthalidyl ester of I is discussed.